PDAC - Pancreatic Ductal Adenocarcinoma

41 clinical trials · Condition

Record	Firm	Date
Magnetic Resonance Imaging (MRI) to Predict Outcomes of Pancreatic Ductal Adenocarcinoma (PDAC) (NCT04700488)	Cedars-Sinai Medical Center	2022-05-19
A Prospective Registry for Patients at High-Risk for Pancreatic Cancer (NCT06151223)	Mayo Clinic	2021-07-13
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors (NCT04900818)	I-Mab Biopharma US Limited	2021-06-29
Nab-Paclitaxel and Gemcitabine Plus Camrelizumab and Radiotherapy for Locally Advanced Pancreatic Adenocarcinoma (NCT04365049)	Sun Yat-sen University	2020-04-01
Defining a Vascular Phenotype of Pancreatic Ductal Adenocarcinoma With CT Perfusion Using Quantitative Radiomics (NCT05669287)	Radboud University Medical Center	2017-12-22
Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma (NCT07573215)	Revolution Medicines, Inc.
Intermediate-size IND for Treatment of Patients With Advanced Cancer Using T Cells Engineered to Express TCR Targeting Mutant KRAS (NCT07614048)	Providence Health & Services

Every clearance here is in the API, with alerts when new ones post.